Explore our website for the latest on MPN Specialist in the U.S. Doctor-reviewed and regularly updated, we offer valuable resources for your health journey.
It's crucial for patients to consult a genuine MPN Specialist as early as possible in their journey with the disease. The early involvement of a MPN specialist can lead to more effective management of the disease and improved patient outcomes. This article outlines key criteria to help you identify whether your doctor is an MPN specialist or just a community oncologist/hematologist who may only treat a few patients annually. By understanding these criteria, you can take proactive steps in your healthcare journey and find a MPN specialist, ensuring that you receive the specialized attention and treatment necessary for managing your condition effectively.
Alabama
Pankit Vachhani, MD* - University of Alabama Birmingham
Arkansas
Kamal Patel, MD – Carti Cancer Center
Peter Emanuel, MD* – CHI St. Vincent
Arizona
Jeanne Palmer, MD - Mayo Clinic
Ravi Krishnadasan, MD* - University of Arizona Cancer Center
Krisstina Gowin, DO - University of Arizona Cancer Center
Misam Zawit, MD* - City of Hope Phoenix
California
Angela Fleischman, MD – UC Irvine Health
Jason Gotlib, MD – Stanford University School of Medicine / Stanford Cancer Center
Catriona Jamieson, MD – UC San Diego Moores Cancer Center
David Leibowitz, MD – Sutter Health / Palo Alto Center
Lloyd Damon, MD – UC San Francisco Health
Casey O'Connell, MD – Keck Medicine of USC
Solomon Hamburg, MD – UCLA Health
Haris Ali, MD* - City of Hope
Idoroenyi Amanam, MD - City of Hope
Mojtaba Akhtari, MD* - Loma Linda University Health
Connecticut
Nikolai Podoltsev, MD – Yale Cancer Center/Smilow Cancer Hospital
Colorado
Brandon McMahon, MD – UC Health University of Colorado Cancer Center
Daniel Pollyea, MD – UC Health University of Colorado Cancer Center
Florida
Candido Rivera, MD – Mayo Clinic, Jacksonville
Sam Reynolds, MD* - Moffitt Cancer Center
Rami Komrokji, MD – Moffitt Cancer Center
Taiga Nishihori, MD* - Moffitt Cancer Center
Kendra Sweet, MD – Moffitt Cancer Center
Andrew Kuykendall, MD – Moffitt Cancer Center
Sangeetha Venugopal, MD* – University of Miami Health System
Chieh-Lin Fu, MD – Cleveland Clinic Florida – Weston
Firas El Chaer, MD - Baptist Health Miami Cancer Institute
Georgia
Vamsi Kota, MD – Augusta University Medical Center, Georgia Cancer Center
Edmund Waller, MD* – Emory Winship Cancer Institute
Nikolaos Papadantonakis, MD* - Emory Winship Cancer Institute
Anthony Hunter, MD - Emory Winship Cancer Institute
Illinois
Olatoyosi Odenike, MD – University of Chicago Comprehensive Cancer Center
Jamile Shammo, MD – Northwestern Medicine
Brady Stein, MD – Northwestern Medicine
Indiana
Larry Cripe, MD – Indiana University Health
Kansas
Abdulraheem Yacoub, MD – University of Kansas Medical Center
Maryland
Linda Resar, MD – Johns Hopkins Medicine
Carole Miller, MD – St. Agnes Hospital & University of Maryland Medical Center
Maria Baer, MD – University of Maryland, School of Medicine
Massachusetts
Ann Mullally, MD – Dana-Farber Cancer Institute
Daniel DeAngelo, MD – Dana-Farber Cancer Institute
Martha Wadleigh, MD – Dana-Farber Cancer Institute
Eric S. Winer, MD – Dana-Farber Cancer Institute
Richard Stone, MD – Dana-Farber Cancer Institute
Jacqueline Garcia, MD – Dana-Farber Cancer Institute
Marlise Luskin, MD – Dana-Farber Cancer Institute
Chi-Joan How, MD* – Dana-Farber Cancer Institute
Gabriela Hobbs, MD – Massachusetts General Hospital Cancer Center
Jonathan Gerber, MD – University of Massachusetts Medical School
Michigan
Moshe Talpaz, MD – University of Michigan Comprehensive Cancer Center
Kristen Marie Pettit, MD – University of Michigan, Michigan Medicine Bone Marrow Transplant & Leukemia
Minnesota
Ayalew Tefferi, MD – Mayo Clinic Rochester
C. Christopher Hook, MD – Mayo Clinic Rochester
Animesh Pardanani, MD – Mayo Clinic Rochester
Alexandra Wolanskyj-Spinner, MD – Mayo Clinic Rochester
Aref Al-Kali, MD* – Mayo Clinic Rochester
William Hogan, MD* - - Mayo Clinic Rochester
Naseema Gangat, MD* - Mayo Clinic Rochester
Missouri
Stephen T. Oh, MD – Siteman Cancer Center at Barnes-Jewish Hospital, Washington University Medicine
Amy Zhou, MD* - Washington University Medicine
New Jersey
Hyung Chan Suh, MD* – Hackensack University Medical Health
New York
Raajit Rampal, MD – Memorial Sloan Kettering Cancer Center
Michael Mauro, MD – Memorial Sloan Kettering Cancer Center
John Mascarenhas, MD – Mount Sinai Cancer Center, Ruttenberg Treatment Center
Ronald Hoffman, MD – Mount Sinai Cancer Center, Ruttenberg Treatment Center
Yelena Ginzburg, MD* – Mount Sinai Cancer Center, Ruttenberg Treatment Center
Marina Kremyanskaya, MD - Mount Sinai Cancer Center, Ruttenberg Treatment Center
Richard T. Silver, MD (retired) – NY Presbyterian-Weill Cornell Medical Center
Ellen Ritchie, MD – NY Presbyterian-Weill Cornell Medical Center
Ghaith Abu-Zeinah, MD – Weill Cornell Medical Center
Michael Samuel, MD – Weill Cornell Medicine
Andrew Schafer, MD – Weill Cornell Medicine
Gail Roboz, MD – Weill Cornell Medicine
Joseph Scandura, MD – Weill Cornell Medicine
Pinkal Desai, MD – Weill Cornell Medicine
Nicole Kucine, MD – Weill Cornell Medicine
Sangmin Lee, MD – Weill Cornell Medicine
Eunice Wang, MD – Roswell Park Comprehensive Cancer Center
North Carolina
Michael Grunwald, MD – Levine Cancer Institute, Atrium Health
Ruben Mesa, MD – Levine Cancer Institute, Atrium Health
Aleksander Chojecki, MD* - Levine Cancer Institute, Atrium Health
Jing Ai, MD* - Levine Cancer Institute, Atrium Health
Rupali Bhave, MD* - Wake Forest Baptist, Atrium Health
Dmitriy Berenzon, MD – Wake Forest Baptist, Atrium Health
Lindsay Rein, MD – Duke Cancer Center
Harry Erba, MD – Duke Cancer Center
Brandi Reeves, MD – UNC Hospital
Ohio
Aaron T. Gerds, MD – Cleveland Clinic Taussig Cancer Institute
John Molina, MD* – Cleveland Clinic Taussig Cancer Institute
Moaath Mustafa Ali, MD* – Cleveland Clinic Taussig Cancer Institute
Jennifer E. Vaughn, MD* - Ohio State East Hospital
Andrew Srisuwananukorn, MD* - Ohio State University Comprehensive Cancer Center
Rebecca Klisovic, MD - UH Cleveland Medical Center
Oregon
Kim-Hien Dao, MD* - Oregon Oncology Specialists
Pennsylvania
Elizabeth Hexner, MD – Penn Medicine
James Rossetti, MD – Hillman Cancer Center
Salman Fazal, MD – Allegheny Health Network
South Carolina
Alexander Coltoff, MD* – MUSC Health, Hollings Cancer Center
Tennessee
Michael Savona, MD – Vanderbilt Ingram Cancer Center
Sanjay Mohan, MD – Vanderbilt Ingram Cancer Center
Katherine Walsh, MD* – Vanderbilt Ingram Cancer Center
Texas
Prithviraj Bose, MD – MD Anderson Cancer Center
Naval G. Daver, MD – MD Anderson Cancer Center
Naveen Pemmaraju, MD – MD Anderson Cancer Center
Lucia Masarova, MD – MD Anderson Cancer Center
Scott Ulmer, MD – Start Center for Cancer Center
Utah
Michael Deininger, MD, Huntsman Cancer Institute at the University of Utah
Josef Prchal, MD – Huntsman Cancer Institute at the University of Utah
Tsewang Tashi, MD – Huntsman Cancer Institute at the University of Utah
Srinivas Tantravahi, MD* – Huntsman Cancer Institute at the University of Utah
Ami Patel, MD* - Huntsman Cancer Institute at the University of Utah
Virginia
Michael Keng, MD* - UVA Health, Emily Couric Clinical Cancer Center
Washington
Bart Scott, MD – Fred Hutchinson Cancer Center
Anna Halpern, MD* – Fred Hutchinson Cancer Center
Washington, DC
Craig Kessler, MD – Lombardi Cancer Center
Wisconsin
Laura Michaelis, MD – Froedtert Hospital
An asterisk (*) denotes physicians that have been added to the list in 2023-2025. Appearance on this list is not an endorsement of any physician, rather, he/she has met the requirements set forth herein to be recognized as an MPN specialist.
What is an MPN Specialist?
The following article has some reasonable criteria to help determine whether your doctor is an MPN specialist or an oncologist / hematologist that sees a couple of patients a year.
If your doctor has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and never published a peer reviewed research paper, he/she isn’t likely to be an MPN specialist. Also, if their bio lists 12+ clinical interests, their focus is NOT likely on MPN’s. 4 to 6 clinical interests would be a reasonable amount to maintain a research study focused on Myeloproliferative Neoplasms. Here several more criteria to consider.
Publisher's Note:
This resource was prepared by David Wallace and another patient advocate, reviewed by an MPN Specialist and published in January, 2018. While some physicians may have advanced degrees (Phd, MS, etc.), all MD's have been screened as specialist in Myeloproliferative Neoplasms. It is an ongoing project that is updated on a regular basis. If you discover a specialist that should be added, please contact us (just below the newsletter sign up form) for an update, it will be greatly appreciated by all.
